Malte Feja1,2, Sebastian Meller1, Lillian S Deking1, Edith Kaczmarek1, Matthew J During3, Richard B Silverman4,5, Manuela Gernert1,2. 1. Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Hannover, Germany. 2. Center for Systems Neuroscience, Hannover, Germany. 3. Ovid Therapeutics, New York, New York, USA. 4. Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois, USA. 5. Department of Pharmacology, Chemistry of Life Processes Institute, Northwestern University, Chicago, Illinois, USA.
Abstract
OBJECTIVE: An attractive target to interfere with epileptic brain hyperexcitability is the enhancement of γ-aminobutyric acidergic (GABAergic) inhibition by inactivation of the GABA-metabolizing enzyme GABA aminotransferase (GABA-AT). GABA-AT inactivators were designed to control seizures by raising brain GABA levels. OV329, a novel drug candidate for the treatment of epilepsy and addiction, has been shown in vitro to be substantially more potent as a GABA-AT inactivator than vigabatrin, an antiseizure drug approved as an add-on therapy for adult patients with refractory complex partial seizures and monotherapy for pediatric patients with infantile spasms. Thus, we hypothesized that OV329 should produce pronounced anticonvulsant effects in two different rat seizure models. METHODS: We therefore examined the effects of OV329 (5, 20, and 40 mg/kg ip) on the seizure threshold of female Wistar Unilever rats, using the timed intravenous pentylenetetrazole (ivPTZ) seizure threshold model as a seizure test particularly sensitive to GABA-potentiating manipulations, and amygdala-kindled rats as a model of difficult-to-treat temporal lobe epilepsy. RESULTS: GABA-AT inactivation by OV329 clearly increased the threshold of both ivPTZ-induced and amygdala-kindled seizures. OV329 further showed a 30-fold greater anticonvulsant potency on ivPTZ-induced myoclonic jerks and clonic seizures compared to vigabatrin investigated previously. Notably, all rats were responsive to OV329 in both seizure models. SIGNIFICANCE: These results reveal an anticonvulsant profile of OV329 that appears to be superior in both potency and efficacy to vigabatrin and highlight OV329 as a highly promising candidate for the treatment of seizures and pharmacoresistant epilepsies.
OBJECTIVE: An attractive target to interfere with epileptic brain hyperexcitability is the enhancement of γ-aminobutyric acidergic (GABAergic) inhibition by inactivation of the GABA-metabolizing enzyme GABA aminotransferase (GABA-AT). GABA-AT inactivators were designed to control seizures by raising brain GABA levels. OV329, a novel drug candidate for the treatment of epilepsy and addiction, has been shown in vitro to be substantially more potent as a GABA-AT inactivator than vigabatrin, an antiseizure drug approved as an add-on therapy for adult patients with refractory complex partial seizures and monotherapy for pediatric patients with infantile spasms. Thus, we hypothesized that OV329 should produce pronounced anticonvulsant effects in two different rat seizure models. METHODS: We therefore examined the effects of OV329 (5, 20, and 40 mg/kg ip) on the seizure threshold of female Wistar Unilever rats, using the timed intravenous pentylenetetrazole (ivPTZ) seizure threshold model as a seizure test particularly sensitive to GABA-potentiating manipulations, and amygdala-kindled rats as a model of difficult-to-treat temporal lobe epilepsy. RESULTS: GABA-AT inactivation by OV329 clearly increased the threshold of both ivPTZ-induced and amygdala-kindled seizures. OV329 further showed a 30-fold greater anticonvulsant potency on ivPTZ-induced myoclonic jerks and clonic seizures compared to vigabatrin investigated previously. Notably, all rats were responsive to OV329 in both seizure models. SIGNIFICANCE: These results reveal an anticonvulsant profile of OV329 that appears to be superior in both potency and efficacy to vigabatrin and highlight OV329 as a highly promising candidate for the treatment of seizures and pharmacoresistant epilepsies.
Authors: Finbar J K O'Callaghan; Stuart W Edwards; Fabienne Dietrich Alber; Mario Cortina Borja; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Marcus Likeman; Andrew L Lux; Mark T Mackay; Andrew A Mallick; Richard W Newton; Melinda Nolan; Ronit Pressler; Dietz Rating; Bernhard Schmitt; Christopher M Verity; John P Osborne Journal: Lancet Child Adolesc Health Date: 2018-08-29
Authors: E B Menachem; L I Persson; P J Schechter; K D Haegele; N Huebert; J Hardenberg; L Dahlgren; J P Mumford Journal: Epilepsy Res Date: 1988 Mar-Apr Impact factor: 3.045
Authors: Jose I Juncosa; Kenji Takaya; Hoang V Le; Matthew J Moschitto; Pathum M Weerawarna; Romila Mascarenhas; Dali Liu; Stephen L Dewey; Richard B Silverman Journal: J Am Chem Soc Date: 2018-01-30 Impact factor: 15.419
Authors: Meir Bialer; Svein I Johannessen; Matthias J Koepp; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White Journal: Epilepsia Date: 2018-10 Impact factor: 5.864